Drug Approval | September 20, 2024
Briefs: Dr. Reddy's Laboratories and Torrent Pharmaceuticals
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Laurus Synthesis receives Form 483 with 5 observations from USFDA
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Subscribe To Our Newsletter & Stay Updated
